Quantcast

Latest Tenofovir Stories

2011-07-13 13:38:40

In a result that will fundamentally change approaches to HIV prevention in Africa, an international study has demonstrated that individuals at high risk for HIV infection who took a daily tablet containing an HIV medication "“ either the antiretroviral medication tenofovir or tenofovir in combination with emtricitabine "“ experienced significantly fewer HIV infections than those who received a placebo pill. These findings are clear evidence that this new HIV prevention strategy,...

2011-07-13 13:37:13

Microbicide Trials Network statement on the Partners PrEP study and the CDC's TDF2 study Today, researchers from two major HIV prevention trials announced favorable results of an approach called oral pre-exposure prophylaxis, or PrEP. One of these trials, the Partners PrEP Study, has provided the strongest evidence yet of PrEP's effectiveness. Information from both studies will need to be fully evaluated before it can be determined what impact they will have on another major trial that is...

2011-07-13 05:21:00

NEW YORK, July 13, 2011 /PRNewswire-USNewswire/ -- Results from two African studies of pre-exposure prophylaxis, or PrEP, released today provide clear evidence that the antiretroviral drugs used to treat HIV can also be used to prevent HIV among heterosexual men and women at risk of HIV infection. "These results are tremendously exciting and confirm that we are at pivotal period in the AIDS epidemic," said Mitchell Warren, AVAC executive director. "Antiretroviral (ARV) drugs for HIV...

2011-07-12 06:00:00

PITTSBURGH and HYDERABAD, India, July 12, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced an expanded licensing agreement between Gilead Sciences Inc. and Mylan's Matrix Laboratories Limited. Matrix has licensed the rights to produce and market generic versions of three Gilead HIV/AIDS therapies, if and when they receive regulatory approval. The Gilead products, which are currently in late-stage clinical development, include: Elvitegravir, an investigational integrase...

2011-05-20 13:35:00

TITUSVILLE, N.J., May 20, 2011 /PRNewswire/ -- The US Food and Drug Administration (FDA) today approved EDURANT(TM) (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment-naive). (Photo: http://photos.prnewswire.com/prnh/20110520/SF06258) EDURANT (pronounced ee' dur ant) was developed as TMC278 (rilpivirine) by Tibotec Pharmaceuticals...

2011-05-18 16:21:29

A new study from the University of North Carolina at Chapel Hill School of Medicine further validates the use of humanized BLT mice in the fight to block HIV transmission. The more than 2.7 million new HIV infections recorded per year leave little doubt that the HIV/AIDS epidemic continues to spread globally. That's why there's the need for safe, inexpensive and effective drugs to successfully block HIV transmission. A new study from the University of North Carolina at Chapel Hill School of...

ba4513bc5fb0584a04062ba9c76f84b0
2011-05-13 05:50:00

An HIV-positive person who takes anti-retroviral drugs immediately after diagnosis, rather than waiting until their health begins to decline, can reduce the risk of spreading the virus to uninfected partners by 96%, according to a major international study. Although antiretroviral therapy was long known to improve the health of people infected with HIV, this is the first study to show a definitive impact on preventing transmission to an HIV-negative partner. "This is excellent news," said...

9dd9ef066dd9141be31d69f8f24ae0571
2011-04-18 13:56:36

Researchers are stopping tests of a daily pill to prevent infection with the AIDS virus in thousands of African women. The study was stopped because partial results show no signs that the drug is preventing the virus. The study found that women taking Truvada, made by Gilead Sciences Inc., are just as likely to get HIV as other women who have been given dummy pills.  Researchers said that even if the study were to continue it would not be able to determine whether the pills help prevent...

2011-03-14 15:05:27

The first human studies of an oral drug regimen to prevent HIV infection in high-risk individuals yielded a promising near 50% reduction in HIV incidence, but a number of issues require additional research before oral pre-exposure prophylaxis (PrEP) can be implemented on a large scale, according to an article in AIDS Patient Care and STDs, a peer-reviewed journal published by Mary Ann Liebert, Inc. (www.liebertpub.com). The article is available free online at www.liebertpub.com/apc After the...

2011-02-28 22:25:44

'New' gel safe and effective in laboratory studies A change in the formulation of tenofovir gel, an anti-HIV gel developed for vaginal use, may make it safer to use in the rectum, suggests research presented today at the 18th Conference on Retroviruses and Opportunistic Infections (CROI). In laboratory tests of rectal tissue, researchers from the Microbicide Trials Network (MTN) found the reformulated gel was less harmful to the lining of the rectum than the original vaginal formulation, and...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.